PARP14

Across TCGA pan-cancer cohorts, PARP14 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARP14 data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PARP14 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PARP14 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, COAD, and CCRCC are the cancer types where PARP14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.972	0.752	.001	50	view →
COAD	DFS	Quartile	All	0.901	1.000	.030	36	view →
CCRCC	OS	Median	All	0.637	1.000	.003	17	view →
LSCC	DFS	Quartile	All	1.000	0.404	.022	3	view →
GBM	DFS	Quartile	All	0.662	0.808	.015	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARP14–LUAD (DFS)

Open the LUAD breakdown →